Maximiliano Tamae Kakazu, MD
Critical Care Medicine · Grand Rapids, MINPI 1811134562
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,551 of the $7,161 with a category attached, or 63.6%. 21 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 27.6% of the total. Reporting peaked in 2023 at $2,464 and has fallen 75.2% since, to $611 in 2025. Among critical care medicine clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 71 payments — averaging $100.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$2K
- Pfizer$1K
- Boehringer Ingelheim$695
- Amgen$616
- GSK$488
- Sanofi$281
- plus $2K from 15 others
What the payments were for
- Consulting fees$2,61036%
- Food & beverage$4,55164%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 9 | $1,979 |
| Pfizer | 1 | $1,110 |
| Boehringer Ingelheim | 8 | $695 |
| Amgen | 6 | $616 |
| GSK | 13 | $488 |
| Sanofi | 4 | $281 |
| Inspire Medical Systems, Inc. | 2 | $260 |
| Harmony Biosciences LLC | 3 | $242 |
| Verona Pharma, Inc. | 2 | $226 |
| AstraZeneca | 7 | $221 |
| Johnson & Johnson | 2 | $201 |
| ZOLL Respicardia, Inc. | 1 | $158 |
| Jazz Pharmaceuticals Inc. | 2 | $141 |
| Actelion Pharmaceuticals US, Inc. | 1 | $130 |
| Pulmonx Corporation | 1 | $126 |
| United Therapeutics Corporation | 1 | $125 |
| Boston Scientific | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Insmed, Inc. | 2 | $33 |
| Philips North America LLC | 1 | $29 |
| AbbVie | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$1,888
- Tavneos$384
- NUCALA$375
- Inspire Upper Airway Stimulation System$260
- remede System$158
- Ohtuvayre$151
- OFEV$145
- UPTRAVI$130
- OPSUMIT$130
- Pulmonx Endobronchial Valve EBV$126
- XYWAV$125
- Monarch Platform$120
- Wakix$117
How this compares
$7,161 in reported general payments places this provider in the 90th percentile of 177 critical care medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $66,182 |
| Spiriva RespimatTiotropium Bromide | 34 | $29,210 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $9,965 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $9,275 |
| Spiriva HandihalerTiotropium Bromide | 14 | $7,221 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $5,525 |
| Atrovent HfaIpratropium Bromide | 11 | $5,007 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 89 | $4,165 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $3,571 |
| Montelukast Sodium | 88 | $1,765 |
| Fluticasone Propionate | 35 | $740 |
| Prednisone | 30 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $488 | $66,18269 claims |
| Boehringer IngelheimSpiriva Respimat | $695 | $29,21034 claims |
| AstraZenecaSymbicort | $221 | $9,96533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 critical care medicine providers in Michigan.
Other critical care medicine in Grand Rapids
- Jeffery WiltGrand Rapids$10K
- Jason WellsGrand Rapids$8K
- Greg MarcoGrand Rapids$5K
- Joseph PitcherGrand Rapids$4K
- Noah JentzenGrand Rapids$2K
- Ruchira SenguptaGrand Rapids$2K
- Ghaleb KhirfanGrand Rapids$2K
- Kevin PattersonGrand Rapids$2K
- Malik KhanGrand Rapids$2K
- Kevin SwiatekGrand Rapids$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.